Dory Freeman

616 total citations
25 papers, 105 citations indexed

About

Dory Freeman is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dory Freeman has authored 25 papers receiving a total of 105 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Dory Freeman's work include Bladder and Urothelial Cancer Treatments (18 papers), Urinary and Genital Oncology Studies (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Dory Freeman is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Urinary and Genital Oncology Studies (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Dory Freeman collaborates with scholars based in United States, Canada and Norway. Dory Freeman's co-authors include Guru Sonpavde, Catherine Curran, Amin H. Nassar, Toni K. Choueiri, Elio Adib, Pier Vitale Nuzzo, Bradley A. McGregor, Sarah Abou Alaiwi, Charlene Mantia and Praful Ravi and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dory Freeman

20 papers receiving 105 citations

Peers

Countries citing papers authored by Dory Freeman

Since Specialization

Citations

This map shows the geographic impact of Dory Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dory Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dory Freeman more than expected).

Fields of papers citing papers by Dory Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dory Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dory Freeman. The network helps show where Dory Freeman may publish in the future.

Co-authorship network of co-authors of Dory Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Dory Freeman. A scholar is included among the top collaborators of Dory Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dory Freeman. Dory Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC). 2024 ·Journal of Clinical Oncology ·Sarmad Sadeghi, Nataliya Mar, Denice Tsao‐Wei, (unknown), Imran Siddiqi, Jon Cogan, (unknown), Dory Freeman, (unknown), Thomas W. Flaig, (unknown), Arash Rezazadeh, Guru Sonpavde, Joaquim Bellmunt	0
2	Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer 2024 ·Clinical Cancer Research ·Konrad H. Stopsack, Joseph Vijai, (unknown), Jacob E. Berchuck, Yelena Kemel, (unknown), Dory Freeman, Gwo‐Shu Mary Lee, Diana Mandelker, David B. Solit, Michael J. Morris, Kathryn L. Penney, Wassim Abida, Kenneth Offit, Lorelei A. Mucci, Philip W. Kantoff, Mark M. Pomerantz	5
3	Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer 2024 ·Journal for ImmunoTherapy of Cancer ·Praful Ravi, Dory Freeman, Jonathan Thomas, Arvind Ravi, Charlene Mantia, Bradley A. McGregor, Jacob E. Berchuck, (unknown), Petra Budde, Behnaz Ahangarian Abhari, (unknown), (unknown), (unknown), (unknown), (unknown), Hans‐Dieter Zucht, Guru Sonpavde	2
4	Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer 2024 ·Clinical Genitourinary Cancer ·William Paul Skelton, (unknown), Jonathan Thomas, (unknown), Rohit Jain, Praful Ravi, Charlene Mantia, Bradley A. McGregor, Pier Vitale Nuzzo, Elio Adib, Talal El Zarif, Mark A. Preston, Timothy N. Clinton, Roger Li, Graeme S. Steele, Wassim Kassouf, Dory Freeman, Gregory R. Pond, Rakesh K. Jain, Guru Sonpavde	0
5	A genetic basis for sex differences in Xp11 translocation renal cell carcinoma 2024 ·Cell ·(unknown), Ananthan Sadagopan, Chunyang Bao, (unknown), Jiao Li, Prathyusha Konda, Richard W. Tourdot, Qingru Xu, Maria Nakhoul, (unknown), (unknown), (unknown), Dory Freeman, Gwo‐Shu Mary Lee, Jonathan L. Hecht, Eric Kauffman, David J. Einstein, Toni K. Choueiri, Cheng‐Zhong Zhang, Srinivas R. Viswanathan	9
6	Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). 2023 ·Journal of Clinical Oncology ·Vadim S. Koshkin, (unknown), Deepak Kilari, (unknown), Omar Alhalabi, Dory Freeman, Arnab Basu, Pedro C. Barata, Mehmet Asım Bilen, Yousef Zakharia, Hamid Emamekhoo, Sumit Shah, Matthew I. Milowsky, Nancy B. Davis, Shilpa Gupta, Christopher Hoimes, Petros Grivas, Joaquim Bellmunt, Matthew T. Campbell, Ajjai Alva	3
7	Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors 2022 ·Clinical Genitourinary Cancer ·Pier Vitale Nuzzo, Elio Adib, (unknown), Catherine Curran, Tyler F. Stewart, Dory Freeman, Amin H. Nassar, Sarah Abou Alaiwi, Ziad Bakouny, Bradley A. McGregor, Toni K. Choueiri, Rakesh K. Jain, Rana R. McKay, Guru Sonpavde	17
8	Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes 2022 ·Clinical Genitourinary Cancer ·Matthew Mossanen, Amin H. Nassar, (unknown), Nieves Martínez Chanzá, Vivek Kumar, Pier Vitale Nuzzo, David J. Kwiatkowski, Judy E. Garber, Catherine Curran, Dory Freeman, Mark A. Preston, Kent W. Mouw, Adam S. Kibel, Toni K. Choueiri, Guru Sonpavde, Huma Q. Rana	5
9	Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. 2022 ·Journal of Clinical Oncology ·Elio Adib, Amin H. Nassar, Talal El Zarif, (unknown), Mehrdad Rakaee, Tarek H. Mouhieddine, Sarah Abou Alaiwi, Dory Freeman, Muhieddine Labban, (unknown), Robert I. Haddad, F. Stephen Hodi, Guru Sonpavde, Marios Giannakis, David A. Braun, Alexander Gusev, Toni K. Choueiri, (unknown), Everett Stone, David J. Kwiatkowski	3
10	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI). 2022 ·Journal of Clinical Oncology ·Elio Adib, Talal El Zarif, Dory Freeman, Muhieddine Labban, Catherine Curran, Bijaya Sharma, Jane Y. Song, Kristen D. Felt, Amin H. Nassar, (unknown), Scott J. Rodig, Toni K. Choueiri, David J. Kwiatkowski, Praful Ravi, Guru Sonpavde	1
11	Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma 2022 ·The Oncologist ·Praful Ravi, Arvind Ravi, Irbaz Bin Riaz, Dory Freeman, Catherine Curran, Charlene Mantia, Bradley A. McGregor, Kerry L. Kilbridge, Chong-xian Pan, (unknown), Yukti Choudhury, (unknown), Guru Sonpavde	5
12	Association of changes in albumin levels with survival and toxicities in patients (pts) with metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV). 2022 ·Journal of Clinical Oncology ·Talal El Zarif, Irbaz Bin Riaz, Elio Adib, Dory Freeman, Ikenna Madueke, (unknown), (unknown), Pier Vitale Nuzzo, Bradley A. McGregor, Charlene Mantia, Praful Ravi, Guru Sonpavde	0
13	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes. 2022 ·Journal of Clinical Oncology ·Wenxin Xu, Maheetha Bharadwaj, (unknown), (unknown), Chris Labaki, Renée Maria Saliby, Ziad Bakouny, Dory Freeman, (unknown), Gwo‐Shu Mary Lee, Bradley A. McGregor, Michelle S. Hirsch, Sachet A. Shukla, David F. McDermott, Sabina Signoretti, Rizwan Romee, Toni K. Choueiri, David A. Braun	1
14	Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC). 2022 ·Journal of Clinical Oncology ·Talal El Zarif, Elio Adib, Clary B. Clish, Sachet A. Shukla, Dory Freeman, Jonathan Thomas, Praful Ravi, (unknown), Bradley A. McGregor, Charlene Mantia, Arvind Ravi, Guru Sonpavde	1
15	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy 2021 ·European Urology ·Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, Mark A. Preston, Brendan Reardon, Jake R. Conway, Catherine Curran, Dory Freeman, (unknown), Guru Sonpavde, Michelle S. Hirsch, Adam S. Kibel, Eliezer M. Van Allen, Kent W. Mouw	13
16	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. 2021 ·Journal of Clinical Oncology ·Vadim S. Koshkin, Yilun Sun, Dory Freeman, (unknown), Christopher Su, (unknown), Ali Raza Khaki, Dimitrios Makrakis, Jayanshu Jain, (unknown), Arnab Basu, Pedro C. Barata, Yousef Zakharia, Mehmet Asım Bilen, Hamid Emamekhoo, Nancy B. Davis, Matthew I. Milowsky, Deepak Kilari, Guru Sonpavde, Ajjai Alva	4
17	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). 2021 ·Journal of Clinical Oncology ·Tyler F. Stewart, Nikhil V. Kotha, Hannah Dzimitrowicz, Dimitrios Makrakis, Ali Raza Khaki, Nicholas I. Simon, Ariel Ann Nelson, Dory Freeman, Tracy L. Rose, Wolfgang Beck, Neal Shiv Chawla, Sumanta K. Pal, Deepak Kilari, Matthew I. Milowsky, Andrea B. Apolo, Petros Grivas, Tian Zhang, Guru Sonpavde, Rana R. McKay	0
18	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma 2021 ·Clinical Genitourinary Cancer ·Rohit Jain, William Paul Skelton, Gregory R. Pond, (unknown), Youngchul Kim, Catherine Curran, Dory Freeman, Pier Vitale Nuzzo, Sarah Abou Alaiwi, Amin H. Nassar, Rakesh K. Jain, Guru Sonpavde	11
19	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma 2021 ·SHILAP Revista de lepidopterología ·Elio Adib, Talal El Zarif, Rohit Jain, William Paul Skelton, Dory Freeman, Catherine Curran, Elie W. Akl, Amin H. Nassar, Praful Ravi, Charlene Mantia, David J. Kwiatkowski, Toni K. Choueiri, Guru Sonpavde	8
20	Five-year Biochemical Control Rates for Stereotactic Body Radiation Therapy for Organ-confined Prostate Cancer: A Multi-institutional Pooled Analysis 2012 ·International Journal of Radiation OncologyBiologyPhysics ·Alan J. Katz, Dory Freeman, Joseph A. Aronovitz, Donald B. Fuller, (unknown), R. Meier, Sean P. Collins, (unknown), Michael L. Steinberg, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact